In the phase II NeoATP trial, the pCR rate reached 69.81% in 53 patients with HER2-positive local ABC (stage IIA–IIIC) receiving four cycles of pyrotinib plus trastuzumab and paclitaxel-cisplatin as neoadjuvant treatment [75]. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.